安科生物(300009.SZ)：PA3-17注射液纳入拟突破性治疗品种

Core Viewpoint - Anke Bio's subsidiary companies have developed a groundbreaking CAR-T cell therapy, PA3-17 injection, which has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) of China [1] Group 1: Company Developments - Anke Bio's subsidiary, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., and Boshengji Anke Cell Technology Co., Ltd. have independently developed the PA3-17 injection [1] - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, aimed at treating adult relapsed/refractory T-lymphoblastic leukemia/lymphoma (R/RT-ALL/LBL) [1]